NEWSROOM | Galderma

AAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs

Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing

AAD 2026: Galderma’s  scientific  presentations

Galderma publishes invitation and agenda for its 2026 Annual General Meeting

AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies

AMWC Monaco 2026: Galderma’s scientific presentations and activities

Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering

Galderma completes successful placement of EUR 500 million Eurobond

Pioneering study deepens our understanding of sensitive skin

Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin

Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency

Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years

Galderma announces triple approval of new state-of-the-art Restylane® syringe in the EU, the U.S., and Canada, reaffirming the company’s position at the forefront of Injectable Aesthetics